Lynx Investment Advisory Biogen Inc. Transaction History
Lynx Investment Advisory
- $135 Billion
- Q2 2024
A detailed history of Lynx Investment Advisory transactions in Biogen Inc. stock. As of the latest transaction made, Lynx Investment Advisory holds 80 shares of BIIB stock, worth $13,916. This represents 0.01% of its overall portfolio holdings.
Number of Shares
80Holding current value
$13,916% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding BIIB
# of Institutions
1,022Shares Held
128MCall Options Held
1.22MPut Options Held
1.4M-
Vanguard Group Inc Valley Forge, PA16.6MShares$2.89 Billion0.08% of portfolio
-
Primecap Management CO Pasadena, CA16.3MShares$2.84 Billion2.78% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.53 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.1MShares$1.23 Billion0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.68MShares$988 Million0.83% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $25B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...